Regulation of Ferroptosis in Human Macrophage by Nitric Oxide Donors

I I Vlasova1, M D Yurkanova2, A A Zolotopup2

  • 1Leading Researcher, Department of Modern Biomaterials; I.M. Sechenov First Moscow State Medical University (Sechenov University), 8/2 Trubetskaya St., Moscow, 119991, Russia.

Insights

Longer-acting nitric oxide (NO) donors, like DTPA, can inhibit ferroptosis in macrophages. This finding suggests potential therapeutic strategies for regulating programmed cell death in immune cells.

Area of Science:

  • Cell Biology
  • Immunology
  • Biochemistry

Background:

  • Ferroptosis is a programmed cell death pathway characterized by iron-dependent lipid peroxidation.
  • Macrophages operate in a pro-oxidative environment, making them susceptible to ferroptosis, necessitating research into its regulation.

Purpose of the Study:

  • To investigate ferroptosis in THP-1 derived macrophages.
  • To compare the efficacy of NO donors with varying half-lives in modulating ferroptosis.

Main Methods:

  • Ferroptosis was induced using GPX4 inhibitors (RSL3, ML-162) and erastin in THP-1 macrophages.
  • Cell death progression was monitored via Alamar blue reduction, LDH release, and LIVE/DEAD assays.
  • Lipid peroxidation was assessed using BODIPY 581/591 C11 probe; ferrostatin-1 confirmed ferroptosis.

Main Results:

  • GPX4 inhibitors dose-dependently induced ferroptosis, a process taking approximately 5 hours to initiate.
  • Erastin showed weak induction but enhanced GPX4 inhibitor-induced ferroptosis.
  • DEA NONOate (2 min half-life) had no effect, while DTPA NONOate (3 h half-life) completely inhibited ferroptosis.

Conclusions:

  • DTPA, a long-acting NO donor, effectively inhibits ferroptosis in THP-1 macrophages.
  • Further research into NO action prolongation mechanisms is needed for therapeutic applications in regulating cellular ferroptosis.